Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body''s natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician''s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina. USD/JPY drops below 156 as US CPI eases and BOJ rate hike expectations increaseAn increase in rate hike expectations from the BOJ and softer US CPI data see USD/JPY turn lower
14:47, 16 January 2025
UK inflation cools in December, GBP/USD attempts to bounce backUK inflation drops more than expected in December, easing some of the fears about the UK economy.
09:41, 15 January 2025
Market Analysis: EUR/GBP Extends Rally but Faces Key ResistanceA worsening economic outlook in the UK is driving the pound lower, pushing EUR/GBP to a two-and-a-half-month high.
14:56, 14 January 2025
AUD/USD hovers near five year low ahead of labour force dataAustralia’s labour market is expected to have cooled in December, according to economist forecasts. The economy is projected to have added 15,000 jobs in the month, lifting the unemployment rate to 4.0%. The lukewarm estimate follows a drop in the unemployment rate to 3.9% in November, owing to a combination of strong full time employment growth and a drop in the participation rate.
12:25, 14 January 2025